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Background/purpose: Nonalcoholic fatty liver disease (NAFLD) is a common condition comprising a wide
spectrum of liver damage strongly associated with type 2 diabetes, obesity, and hyperlipidemia. The
pathogenesis of fatty liver is multifactorial, and it has been suggested that the presence of insulin
resistance (IR) is an essential requirement for the accumulation of hepatocellular fat. Although NAFLD
may affect people of any age, in general, increasing age is associated with increasing prevalence. The aim
of this study was to determine the prevalence of fatty liver and its inﬂuence on age and sex; and to assess
the association of different degrees of fatty liver to IR and metabolic syndrome.
Materials and methods: The study was performed in 8350 alcohol- and virus-negative individuals who
underwent routine physical check-up at the health evaluation centre of Mackay Memorial Hospital, from
February 2004 to May 2009. They underwent clinical examination, anthropometry, biochemical tests
including serum fasting insulin, and routine liver ultrasonography. Steatosis was graded as absent, mild,
moderate, or severe.
Results: The overall prevalence of fatty liver was 34.40% with the prevalence of fatty liver being signif-
icantly higher in males than in females (22.34 vs. 12.06%, p ¼ 0.015). A progressive increase in the means
of a homeostasis model assessment of IR (HOMA-IR), body mass index, systolic blood pressure, plasma
triglyceride, alanine aminotransferase, low-density lipoprotein-cholesterol and glucose level and
decrease in high-density lipoprotein-cholesterol (p < 0.001 and p < 0.05) was observed from the group
without steatosis to the groups with mild, moderate, and severe steatosis. Severe steatosis was associated
with the clustering of risk factors for metabolic syndrome. Individuals with metabolic syndrome and a
more pronounced HOMA-IR had a higher prevalence of moderate to severe steatosis (p < 0.001 and
p < 0.05) compared to those with HOMA-IR below the median.
Conclusion: Fatty liver can be considered as the hepatic consequence of metabolic syndrome, speciﬁcally
IR. There is a high prevalence of metabolic syndrome and fatty liver among the elderly population.
Metabolic disorders are closely related to fatty liver; moreover, fatty liver appears to be a good predictor
for the clustering of risk factors for metabolic syndrome.
Copyright  2013, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Nonalcoholic fatty liver disease (NAFLD) represents one of the
most common liver disorders in western industrialized countrieslated to the manuscript.
vision of Gastroenterology,
Hospital, Number 92, Section
hih).
iwan Society of Geriatric Emergenand recent studies indicate that fatty liver is an emerging problem
in the AsiaePaciﬁc region, affecting 12e24% of community sub-
groups1,2. Prevalence studies in the adult general population and
among those undergoing a master health check-up have shown a
prevalence of NAFLD ranging from 11.5% to 41% in Taiwan3,4.
NAFLD is a common condition comprising a wide spectrum of
liver damage strongly associated with type 2 diabetes, obesity, and
hyperlipidemia.5,6 The pathogenesis of fatty liver is multifactorial
and it has been suggested that the presence of insulin resistancecy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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cellular fat7,8. IR has been demonstrated to unify NAFLD to meta-
bolic syndrome, i.e., the clustering of glucose intolerance and/or
diabetes, hyperinsulinemia, increased levels of triglycerides and
decreased high-density lipoprotein (HDL)-cholesterol, hyperten-
sion, and central and overall obesity9e11. Using the homeostasis
model assessment (HOMA) method, IR was the laboratory ﬁnding
mostly associated with the presence of NAFLD, irrespective of body
mass index (BMI), fat distribution, or glucose tolerance12. NAFLD
may be considered as an additional feature of the metabolic syn-
drome, with speciﬁc hepatic IR12.
The aim of the study was to determine the prevalence of fatty
liver and its inﬂuence on age and sex, and to assess the association
of different degrees of fatty liver to IR and metabolic syndrome.Table 1
Clinical characteristics of the study population.
Male (n ¼ 4524) Female (n ¼ 3826) p
Age (y) 44.9  11.4 45.9  12.1 0.065
Fatty liver 1866 (41.24) 1007 (26.31) 0.015
Mild 1477 (32.64) 785 (20.51) <0.001
Moderate 341 (7.53) 201 (5.25) <0.001
Severe 48 (1.06) 21 (0.54) <0.01
HOMA IR (%) 2.8  2.0 2.9  1.9 0.380
BMI (kg/m2 ) 24.5  3.2 22.5  3.5 0.031
WHR 0.9  0.1 0.8  0.1 <0.01
SBP (mmHg) 121.7  15.4 126.1  18.2 0.098
DBP (mmHg) 76.2  9.8 71.2  10.1 0.082
FPG (mg/L) 992  231 952  224 0.568
PPG (mg/L) 1135  20 1127  26 0.689
HbA1c 5.6  1.1 5.5  0.9 0.298
ALT (U/L) 35.7  7.4 22.4  2.3 0.262
TC (mg/L) 1934  31 1902  57 0.212
LDL-C (mg/L) 1256  32 1171  31 0.041
HDL-C (mg/L) 493  12 616  15 0.002
Triglyceride (mg/L) 1332  86 922  62 0.022
p < 0.05 is considered statistically signiﬁcant.
Data are presented as n (%) or mean  standard deviation.
ALT ¼ alanine aminotransferase; BMI ¼ body mass index; DBP ¼ diastolic blood
pressure; FPG ¼ fasting plasma glucose; HDL-C ¼ high-density lipoprotein choles-
terol; HOMA-IR ¼ homeostasis model of insulin resistance; LDL-C ¼ low-density
lipoprotein cholesterol; PPG ¼ postprandial plasma glucose; SBP ¼ systolic blood
pressure; TC ¼ total cholesterol; WHR ¼ waist-hip-circumference ratio.2. Materials and methods
The study was performed on 8350 alcohol- and virus-negative
consecutive individuals (4524 male and 3826 female) who under-
went routine physical check-up at the health evaluation center of
Mackay Memorial Hospital, from February 2004 to May 2009. They
underwent clinical examination including systolic and diastolic
blood pressure, anthropometry, biochemical tests including serum
fasting insulin, and routine liver ultrasonography. All participants
gave informed consent for the use of their clinical and laboratory
results for research purposes. This study was approved by the hos-
pital ethics institutional review board committee (09MMHIS020).
To be eligible for the study, all participants needed to fulﬁll the
following criteria: no history of current or past excessive alcohol
drinking as deﬁned by average daily consumption of alcohol more
than 20 g; negative tests for the presence of hepatitis B surface
antigen and antibody to hepatitis C virus; and absence of clinical,
biochemical, and ultrasound ﬁndings consistent with liver cirrhosis
and other chronic liver diseases. None of the participants were
taking amiodarone or other drugs known to promote fatty liver
disease.
Individuals underwent routine biochemical evaluation
including alanine aminotransferase (ALT), fasting total cholesterol,
low-density lipoprotein-cholesterol and HDL-cholesterol, tri-
glycerides, glucose, and serum fasting insulin.
Waist and hip circumference, height, and weight were recorded
andBMIwas calculatedasweightdividedbyheight squared (kg/m2).
The HOMA of IR (HOMA-IR) is a mathematic model based on the
product of the fasting insulin and glucose level that provide similar
measures of insulin sensitivity13. The HOMA-IR is calculated from
serum fasting insulin (mU/L)  fasting glucose (mM) divided by
22.5. IR  2.7 is deﬁned as increased IR14.
Following the revised Adult Treatment Panel III (ATP III) criteria
of metabolic syndrome for the Asian Studies15e17, metabolic syn-
drome was diagnosed in the concomitant presence of any three of
the following factors: (1) waist circumference (central
obesity) 90 cm (men) and80 cm (women), and/or BMI 25 kg/
m2 in both sexes; (2) fasting plasma glucose  5.6 mM or  1.0 g/L;
(3) triglyceride1.7mMor1.5 g/L; (4)HDL-cholesterol<1.03mM
or < 0.4 g/L (men) and < 1.29 mM or < 0.5 g/L (women); and (5)
systolic/diastolic blood pressure  130/85 mmHg.
Liver ultrasound scanningwas performed to assess the degree of
steatosis. All ultrasound examinations were performed by a trained
hepatologist, using a Toshiba Nemio SSA-550A instrument equip-
ped with a convex 3.5 MHz probe (Toshiba, Tochigi-ken, Japan).
Steatosis was graded on the basis of abnormally intense, high-level
echoes arising from liver parenchyma, liver-kidney difference in
echo amplitude, echo penetration into the deep portion of the liver,
and clarity of liver blood vessel structure18,19. Steatosis wasassessed semiquantitatively as absent (0), mild (1), moderate (2), or
severe (3).
Statistical analysis was performed using the SPSS statistical
software for Windows, version 12 (SPSS Inc., Chicago, IL, USA). Data
are expressed as the mean  standard deviation for continuous
variables. Student t tests for unpaired data were used for the
comparison of mean values. Group comparisons were performed
by the use of analysis of variance. Proportions and categorical
variables were tested by the Chi-square test. All p-values are two
tailed; p < 0.05 was considered to indicate statistical signiﬁcance.3. Results
The main clinical features of the study population are reported
in Table 1. In the group of 8350 individuals who underwent liver
ultrasound scanning, steatosis was found in 34.40% (22.34% in
males and 12.06% in females), of which 27.08% had mild steatosis,
6.49% had moderate fatty liver, and 0.82% had severe steatosis.
Clinical characteristics and laboratory data of participants with
different degrees of steatosis on ultrasound scan and a control
group without steatosis are reported in Table 2. A progressive,
statistically signiﬁcant increase in mean age (p ¼ 0.013), mean BMI
(p < 0.001), waist:height ratio (p < 0.05), systolic blood pressure
(p < 0.001), plasma fasting and postprandial glucose (p < 0.05
and p < 0.01, respectively), ALT (p < 0.001), triglycerides
(p < 0.001), and low-density lipoprotein-cholesterol (p < 0.001)
and a decrease in mean HDL-cholesterol (p < 0.001) were recorded
from the control group to the groups with increasing severity of
liver steatosis (Table 2). A statistically positive increase was also
observed in IR, as assessed by mean HOMA values (p < 0.001). No
between-group differences were observed for diastolic blood
pressure (p ¼ 0.18) and serum total cholesterol (p ¼ 0.31; Table 2).
Of the 8350 participants, 2873 (34.40%) were diagnosed as hav-
ing fatty liver. Theprevalence of fatty liverwas signiﬁcantly higher in
males than in females (22.34% vs. 12.06%, p ¼ 0.015). The total
prevalence of fatty liver increasedwith age and the peak prevalence
(46.7%)was reached at age 70 years (Table 3). The peak prevalence
inmaleswas at age 40e49 years, whereas that in femaleswas at age
60e69 years. The prevalence of fatty liverwas signiﬁcantly higher in
Table 2











Sex (M/F) 2658/2819 1477/785 341/201 48/21
Age (y) 43.9  1.2 44.5  1.1 46.8  1.1 56.9  1.3 0.013
BMI (kg/m2) 22.8  2.7 25.2  2.6 28.3  3.5 30.7  4.5 <0.001
WHR 0.82  0.07 0.88  0.06 0.93  0.07 0.96  0.05 <0.05
SBP (mmHg) 115.9  16.6 122.7  16.7 129.2  16.1 133.2  16.2 <0.001
DBP (mmHg) 71.7  9.9 76.5  10.1 80.3  10.2 80.8  10.5 0.18
HOMA-IR (%) 1.19  1.1 2.2  1.7 2.9  2.1 3.3  4.3 <0.001
FPG (mg/L) 932  175 1013  249 1102  337 1226  508 <0.05
PPG (mg/L) 1080  369 1212  507 1384  532 1508  472 <0.01
HbA1c 5.4  0.7 5.8  1.0 6.1  1.3 6.2  1.3 <0.05
ALT (U/L) 23.5  33.6 35.1  23.7 49.2  31.5 62.6  38.8 <0.001
TC (mg/L) 1862  338 1971  348 2041  345 2055  467 0.31
LDL-C (mg/L) 1154  306 1283  315 1323  313 1426  438 <0.001
HDL-C (mg/L) 598  147 493  117 459  114 423  123 <0.001
TG (mg/L) 858  51 1452  85 1517  34 1847  81 <0.001
p < 0.05 is considered statistically signiﬁcant.
Data are presented as mean  standard deviation.
ALT ¼ alanine aminotransferase; BMI ¼ body mass index; DBP ¼ diastolic blood
pressure; FPG ¼ fasting plasma glucose; HDL-C ¼ high-density lipoprotein choles-
terol; HOMA-IR ¼ homeostasis model of insulin resistance; LDL-C ¼ low-density
lipoprotein cholesterol; PPG ¼ postprandial plasma glucose; SBP ¼ systolic blood
pressure; TC ¼ total cholesterol; WHR ¼ waist-hip-circumference ratio.
Table 4
Homeostasis model of insulin resistance (HOMA-IR) and prevalence of liver steatosis
with different clustering of risk factors (as deﬁned in materials and methods on the
basis of the revised ATP III criteria of metabolic syndrome for the Asian Study).
No. of associated risk factors
0 (n ¼ 3814) 1e2 (n ¼ 3621) 3e5 (n ¼ 915) p
Age (y) 48.54  1.50 48.85  1.95 50.14  1.79 0.047
Mild/absent FL 47.55 35.43 13.15 <0.001
Moderate FL 1.01 7.41 13.77 0.03
Severe FL 0.18 0.87 25.19 <0.001
ALT (U/L) 18.76 34.55 41.68 <0.001
Mean HOMO-IR 1.0  0.95 1.7  1.37 3.02  1.48 0.007
p < 0.05 is considered statistically signiﬁcant.
Data are presented as %.
ALT ¼ alanine aminotransferase; FL ¼ fatty liver; HDL-C ¼ high-density lipoprotein
cholesterol.
Table 5
Prevalence of risk factors (as deﬁned in materials and methods on the basis of the
revised ATP III criteria of metabolic syndrome for the Asian Study) and liver steatosis
in participants with metabolic syndrome according to homeostasis model of insulin
resistance (HOMA-IR).
H.-Y. Cheng et al.196males than in females prior to age 50 years, but was signiﬁcantly
higher in females than in males after age 50 years.
The metabolic syndrome was diagnosed in 915 participants
fulﬁlling three minimal criteria in accordance with the recom-
mendations of the revised ATP III criteria of metabolic syndrome for
the Asian Studies15e17. In this group, the prevalence of severe fatty
liver was 25.19%, compared with 0.87% and 0.18%, in 3621 partici-
pants with only one or two risk factors and in 3814 individuals with
no risk factors (p< 0.001), respectively. A statistically positive trend
was also observed between mean serum ALT values and mean
HOMO-IR (p < 0.001 and p < 0.007; Table 4).
In participants with the metabolic syndrome, those with a more
pronounced IR (HOMO-IR above the median) had a signiﬁcantly
higher prevalence of severe fatty liver (31.34%, p< 0.001) compared
with those whose HOMA-IR was below the median (Table 5).
Similarly, individuals with amore pronounced IR had a clustering of
risk factors of the metabolic syndrome such as hyper-
triglyceridemia (p ¼ 0.003), low HDL cholesterol (p < 0.001) and
hyperglycemia (p ¼ 0.011), except waist circumference (p ¼ 0.186)
and blood pressure (p¼ 0.224). IR did not differentiate between the
presence and absence of a high serum ALT (p ¼ 0.08).
4. Discussion
NAFLD is a metabolic disorder originally assumed to be largely
conﬁned to residents of afﬂuent, industrialized western countries.Table 3
Prevalence of fatty liver in the study populations.







16e19 22/385 (5.7) 20/145 (13.8) 2/240 (0.8) 0.18
20e29 176/398 (19.1) 166/408 (40.7) 10/190 (5.3) 0.03
30e39 296/1230 (24.1) 263/649 (40.5) 33/581 (5.7) 0.01
40e49 755/2150 (33.1) 543/1042 (52.1) 212/1208 (17.5) <0.001
50e59 607/1820 (34.6) 325/990 (32.8) 282/930 (33.9) 0.15
60e69 675/1625 (41.5) 439/999 (39.9) 276/626 (44.1) 0.08
70 342/742 (46.7) 170/351 (43.4) 172/391 (43.9) 0.01
p < 0.05 is considered statistically signiﬁcant.
*p value for comparison between sexes.However obesity and IR, the common substrates of NAFLD, are not
restricted to the west, as witnessed by their increasingly universal
distribution20. In particular, there has been an upsurge in obesity-
related metabolic syndrome in the AsiaePaciﬁc region, where
rates of NAFLD are between 12% and 24% of the general
population1,2.
NAFLD is a clinical condition that comprises a wide spectrum of
liver damage, ranging from simple steatosis to steatohepatitis,
advanced ﬁbrosis, and cirrhosis in patients with normal or elevated
serum ALT10,21. NAFLD is associated with the clinical conditions
found in metabolic syndrome including obesity, hypertension,
diabetes, and dyslipidemia. It is likely that NAFLD is the hepatic
manifestation of metabolic syndrome, and that IR is a key factor in
disease pathogenesis9,10. Central obesity seems to be an important
risk factor for NAFLD, even in patients with normal BMI andmay be
the key link for IR. Likewise, the lipid disorders associated with the
metabolic syndrome, such as hypertriglyceridemia and hypercho-
lesterolemia, are also found in metabolic syndrome and may in-
crease the risk of NAFLD2,22.
Metabolic syndrome is characterized by a cluster of major car-
diovascular risk factors and by the presence of IR. IR is responsible
for causing abnormalities of lipid storage and lipolysis in insulin-
sensitive tissues, which may induce an increased fatty acid ﬂux
from adipose tissue to the liver and cause steatosis. IR may also
cause lipid peroxidation, which in turn may activate inﬂammatory
cytokines and promote the progression of innocent steatosis to
nonalcoholic steatohepatitis and liver cirrhosis. Fatty liver itself is





Median age (y) 50.7  11.8 51.2  11.9 0.04
Mild/absent fatty liver 50.47 19.28 <0.001
Moderate fatty liver 11.87 21.40 0.031
Severe fatty liver 7.48 31.34 <0.001
ALT  1.5 32.99 32.33 0.08
Increased waist circumference 66.19 59.10 0.186
Hypertriglyceridemia 32.33 42.99 0.003
Low HDL-cholesterol 68.89 84.91 <0.001
Hyperglycemia 23.68 31.78 0.011
High blood pressure 59.53 62.00 0.224
p < 0.05 is considered statistically signiﬁcant.
Data are presented as %.
ALT ¼ alanine aminotransferase; HDL-cholesterol ¼ high-density lipoprotein
cholesterol.
Nonalcoholic Fatty Liver Disease 197disorders, but also in lean individuals with normal glucose toler-
ance, because hepatic fat accumulation can lead specially to hepatic
IR10,12. In our study, severity of fatty liver was positively related to
an increase in BMI, waist circumference, systolic blood pressure,
hyperlipidemia, and blood glucose levels (Table 2). Severe steatosis
was associated with the clustering of the ﬁve clinical and
biochemical features proposed for the clinical diagnosis of meta-
bolic syndrome. Individuals with metabolic syndrome with a more
pronounced HOMA-IR had a higher prevalence of moderate to
severe steatosis compared with those with HOMA-IR below the
median (Tables 4 and 5). The presence of NAFLD is associatedwith a
high risk of developing T2DM, dyslipidemia (high plasma triglyc-
eride and/or low plasma high-density lipoprotein cholesterol con-
centrations), and hypertension23. Therefore it is important to
control body weight and waist circumference to reduce blood
glucose level, triglyceride, and blood pressure.
In addition to metabolic disorders, other risk factors for NAFLD
have been identiﬁed from the Asian study. These include advanced
age, sex, low education, physical inactivity, high fat intake, over-
eating, recent weight gain and expandingwaistline, a family history
of obesity and/or diabetes, and a family history of fatty liver. No
close relationship has been observed between current cigarette
smoking or chronic viral hepatitis and NAFLD24,25. Although NAFLD
may affect people of any age and has been described in most racial
groups, in general, increasing age is associated with increasing
prevalence of NAFLD. Age as an independent risk of developing a
more severe NAFLD or hepatitis ﬁbrosis has been proved, with
advancing age linked to an increased risk of death23. Female sex is
not a risk for NAFLD. Men outnumber women in most of the pub-
lished series from Asia-Paciﬁc region; however, in two studies, a
bimodal age distribution has been observed; the peak prevalence of
NAFLD in men occurs earlier (40e49 years) than for women (> 50
years)23,25. In women, prevalence peaks once age exceeds 50 years;
it is consistent with experimental evidence that estrogen may be
partially protective against steatosis24e26. In our study, the peak
prevalence in males was reached at age 40e49 years, whereas in
females it was at age 60e69 years. The prevalence of fatty liver was
signiﬁcantly higher in males than in females prior to age 50 years,
but was signiﬁcantly higher in females than in males after age 50
years (Table 3). The pathogenesis of male predominance in NAFLD
may include more common accumulation of visceral fat and much
closer association between deep subcutaneous adipose tissue and
IR. Estrogen is speculated to be able to suppress visceral fat accu-
mulation and to increase subcutaneous fat accumulation27.
Although different clinical and biochemical criteria may be
proposed for the diagnosis of metabolic syndrome, in our study,
clinical diagnosis was based on patients fulﬁlling three minimal
criteria in accordance with the recommendations of the revised
ATP III criteria of metabolic syndrome for the Asian Studies15e17.
However, when the diagnosis of metabolic syndrome is based on
the broad clinical criteria proposed on the ATP III report, there may
be multiple clinical and biochemical presentations depending on
the different clustering of risk factors and on the interplay between
genetic variation and environmental factors. As a consequence of
such variability, patients may also have normal insulin sensitivity
and secretion, or normal insulin sensitivity and decreased insulin
secretion; in addition to high IR and insulin secretion.
Insulin has important metabolic effects on multiple organ sys-
tems. Although the term insulin resistance is usually used to
describe impaired insulin-mediated glucose uptake in skeletal
muscle, IR associatedwith obesity and NAFLD also involves the liver
(impaired insulin-mediated suppression of glucose production)
and adipose tissue (impaired insulin-mediated suppression of
lipolysis). The presence of steatosis is an important marker of
multiorgan IR, independent of BMI, percentage of body fat, andvisceral fat mass28,29. However, it is not known whether NAFLD
causes or is a consequence of IR, or possibly both.
HOMA-IR, the prevalence of severe fatty liver, and mean ALT
values were signiﬁcantly higher in individuals with metabolic
syndrome compared with those with less than three of the ﬁve
clinical features considered for its diagnosis. However, participants
fulﬁlling the ATP III criteria for the diagnosis of metabolic syndrome
greatly differed with respect to insulin sensitivity; yet the preva-
lence of fatty liver was signiﬁcantly higher in those with HOMA-IR
above the median, compared with those below the median.
Conversely, in this group, IR did not differentiate between the
presence and absence of ALTelevation (Tables 4 and 5). Moreover IR
was associated with severe fatty liver independently from poten-
tially confounding factors such as age, BMI, and high fasting
glucose.
Our ﬁndings stress the heterogeneous clinical and biochemical
presentations of individuals with metabolic syndrome when the
diagnosis is based on broad ATP III clinical criteria and demonstrate
that those with increased insulin resistance have a higher preva-
lence of severe fatty liver. This result further conﬁrms the patho-
genic role of IR in the development of NAFLD. Metabolic disorders
are closely related to fatty liver;moreover, fatty liver appears to be a
good predictor for the clustering of risk factors for metabolic
syndrome.
The worrying rise in the global prevalence of NAFLD/nonalco-
holic steatohepatitis and the slow progress in identifying effective
medical therapy for this condition highlights the importance of
preventive measures. Screening for early detection and proper
management of IR is pivotal. NAFLD should be suspected when
there are metabolic risk factors or abnormal liver function tests
and/or strong evidence of steatosis on hepatic ultrasonography.
Diagnosis by abdominal ultrasonography, assessment of liver
function and liver-related complications, exclusion of alcohol
toxicity and hepatitis B and C, and screening for IR and metabolic
syndrome are required for initial assessment. Changes in lifestyle,
which include an increase in physical activity (regular aerobic ex-
ercise appropriate for the age and health of the individual) and
healthy dietary habits, should be encouraged. Those at risk should
be closely monitored to ensure the desired results, for the pre-
vention of diabetes, cardiovascular disease, liver cirrhosis, and
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